Investment Banking
Joint Bookrunner on Capricor Therapeutics’ $172.5MM CMPO
December 11, 2025
Oppenheimer & Co. Inc. acted as Joint Bookrunner on Capricor Therapeutics’ $172.5MM Confidentially Marketed Public Offering
Capricor Therapeutics, Inc., a biotechnology company developing transformative cell and exosome-based therapeutics, announced the pricing of its underwritten public offering of 6,900,000 shares of common stock at a public offering price of $25.00 per share.
The Company intends to use the net proceeds from the offering for the continued development of its product candidates, manufacturing of its product candidates, working capital and general corporate purposes.
Healthcare Life Sciences Investment Banking
Name:
Michael A. Margolis, R.Ph.
Title:Senior Managing Director, Head of Healthcare Life Sciences Investment Banking
Healthcare Equity Capital Markets
Name:
Andy Linderman
Title:Managing Director, Healthcare Capital Markets Investment Banking
Name:
James Yoo
Title:Managing Director, Healthcare Capital Markets Investment Banking
DISCLOSURES
This notice is provided for informational purposes only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
Oppenheimer & Co. Inc. Transacts Business on all Principal US Exchanges and is a Member of SIPC 8655159.1